(CADL) Candel Therapeutics, Inc. Business Model Canvas Research

Academic and physician investigators are core partners for Candel Therapeutics, Inc.; they run protocols in urology, oncology, neurosurgery, and radiation oncology, and their peer-reviewed work builds clinical trust. Their site-level expertise matters most in tough tumors like glioblastoma and pancreatic cancer, where patient selection and procedure quality can make or break results.

• Drive trial execution
• Support peer-reviewed data
• Boost medical credibility
• Enable hard-to-treat cancer studies

Candel Therapeutics, Inc. relies on FDA dialogue and capital providers to keep its clinical-stage programs moving, because trial work, manufacturing, and regulatory filings all need steady cash. Public-market investors and underwriters matter too, since biotech access to equity can decide whether the Company can fund the next study readout or submission window.

• FDA feedback shapes trial design.
• Equity funding pays for trials.
• Underwriters support liquidity access.

Candel Therapeutics, Inc. must keep gene-therapy CMC tight: clinical-grade supply, stability, and release testing have to stay ready as programs move from Phase I into later trials. In 2025, Candel Therapeutics reported $80.8 million in cash, cash equivalents, and marketable securities, which supports the long lead times and repeated batch checks this work needs.

• Keep clinical-grade lots on hand
• Prove stability across storage time
• Pass release tests before dosing
• Scale quality as trials advance

Regulatory strategy and trial operations keep Candel Therapeutics, Inc. moving across its INDs, protocol amendments, and FDA meetings. The team also has to route safety reports and trial records across each program, which lowers development risk and helps studies stay aligned with federal review rules.

• Maintain INDs and FDA contact
• File protocol amendments fast
• Track safety reports across trials
• Keep documentation audit-ready

Candel Therapeutics’ key resource is its scientific and clinical team: experts in oncology, virology, immunotherapy, and trial ops who design, run, and read out studies for its 2 lead clinical programs, CAN-2409 and CAN-3110. In a small biotech, this institutional know-how is the asset that turns science into data and value.

• Specialized team drives trial design and execution.
• Expertise is critical in 2 lead programs.

Candel Therapeutics, Inc. depends on cash and equity financing capacity because clinical trials, GMP manufacturing, and FDA work burn capital fast. As a clinical-stage biotech, it relies on public-market access to fund ongoing development and keep programs moving without interruption.

• Funds trials and manufacturing
• Supports regulatory filings
• Uses public equity for runway

Candel Therapeutics, Inc. has more than one clinical shot on goal: CAN-2409 is being studied in localized prostate cancer and other solid tumors, while CAN-3110 targets recurrent high-grade glioma. That mix spreads risk across tumor types and stages, which investors often reward in biotech.

• 2 clinical programs
• Multiple indications
• Risk spread across tumor types
• Diversification can support valuation

Candel Therapeutics, Inc.'s intratumoral programs can be tested with standard-of-care regimens, which matters in big oncology markets like U.S. lung cancer, with 238,340 new cases and 127,070 deaths in 2023. If combination therapy lifts response rates, it can widen use in tumor types that already have strong treatment backbones.

• Pairs with standard-of-care
• Targets larger patient pools
• Can raise response rates

Candel Therapeutics uses investor relations to keep shareholders and analysts informed on trial milestones, readouts, and financing, which matters in public biotech where credibility can move valuation and capital access. The message has to stay clear and timely, because each data update can affect how the market prices the pipeline.

• Shareholders want constant updates
• Trial data drives valuation
• Financing news affects runway
• Credibility supports capital access

Candel Therapeutics, Inc. uses patient-centered trial support to keep cancer participants informed, scheduled, and followed at the site level, which helps reduce missed visits and missing data. In oncology trials, clear guidance on risks, procedures, and follow-up is tied to better retention and cleaner datasets.

• Clear visit and risk explanations
• Site-level coordination and follow-up
• Better retention and data completeness

Candel Therapeutics, Inc. uses investor relations, 10-Qs, 10-Ks, earnings decks, and calls to show pipeline progress, cash runway, and milestone timing. For a pre-revenue biotech, that disclosure flow is what keeps capital markets access open and shapes how investors price the next raise.

• Pipeline status and trial updates
• Cash runway and funding needs
• Milestones that move valuation

Candel Therapeutics, Inc. uses its corporate website as a 24/7 public channel for pipeline, trial, and company updates, so one source can serve patients, investors, and partners at low cost. It also supports hiring and outreach with consistent messaging across all audiences.

• Public pipeline and company updates
• Supports recruiting and IR
• Low-cost, always-on channel
• Helps partner outreach

CAN-3110 targets patients with recurrent glioblastoma, a group with very few options and a median survival after recurrence often measured in months; 5-year survival for glioblastoma is still about 7%. This segment needs neurosurgical and neuro-oncology teams because delivery and follow-up depend on complex brain-tumor care.

• Recurrent GBM has high mortality
• CAN-3110 is in this use case
• Specialist centers are required

Oncology hospitals, cancer centers, and specialist physicians are the key gatekeepers for Candel Therapeutics, Inc.: they enroll patients in trials and decide later use of therapies that must be given in specialized settings. In practice, this B2B base is concentrated in a limited number of high-volume cancer centers, so their acceptance drives both clinical validation and commercial reach.

• Trial enrollment starts with treating physicians.
• Specialized centers drive adoption.
• Gatekeeper support shapes reach.

Regulatory and legal expense stays high for Candel Therapeutics, Inc. because FDA meetings, IND and BLA filings, patent work, and compliance all need outside counsel and staff time. As a public company, Candel Therapeutics, Inc. also pays for SEC reporting, audit support, and legal review tied to equity raises and disclosures.

• FDA and SEC work drives steady cash spend.
• Patent defense protects platform value.
• Public reporting adds legal and accounting fees.

Candel Therapeutics, Inc.'s general and administrative overhead covers core corporate work like finance, HR, facilities, and IT, which are needed to run a Needham, Massachusetts-based public company. In biotech, stock-based compensation can also be a material part of this line item, adding non-cash expense to the cash cost base.

• Finance, HR, facilities, and IT support operations.
• Fixed public-company overhead stays in place.
• Stock-based compensation can be material.

Milestone payments can come from partners when Candel Therapeutics, Inc. hits clinical, regulatory, or commercial steps, so cash arrives as programs move from Phase 1 to Phase 3 and beyond. This matters most for late-stage assets like CAN-2409 and CAN-3110, where each success point can reduce funding strain and lift deal value.

• Paid at clinical, regulatory, commercial milestones
• Best for late-stage, high-risk assets
• Aligns cash with progress

If Candel Therapeutics, Inc. out-licenses a program, it can earn royalties on future sales plus upfront or milestone license fees, which bring in non-dilutive cash. This fits an IP-led biopharma model, where monetizing one asset can fund the next one without issuing new shares.

• Royalties: share of future product sales

• License fees: upfront, non-dilutive cash

• Best fit for IP-heavy biopharma models